Antiplatelet therapy is the cerstone for the management of patients with coronary artery disease. In the past two decades, the study on individualized antiplatelet therapy has never been more prosperous accompanied with the rapid growth of percutaneous coronary interventions (PCIs).[1] Thrombosis and bleeding are the two sides of a coin. The fundamental idea of optimal antiplatelet therapy is to weight its pros and cons carefully, in order to maximize the benefit and minimize the potential risk simultaneously. According to this principle, tens of thousands studies have been launched and published and have changed the current guidelines and clinical practice. However, there are still many questions unsolved in this area.